| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/29/2003 | EP1279682A1 Amphiphilic biodegradable block copolymers and self-assembled polymer aggregates formed from the same in aqueous milieu |
| 01/29/2003 | EP1279406A1 Transporters and drug delivery system by using the same |
| 01/29/2003 | EP1279405A1 Drugs retained in target tissue over long time |
| 01/29/2003 | EP1279403A1 Pernasally absorbable insulin preparations |
| 01/29/2003 | EP1279402A1 Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules |
| 01/29/2003 | EP1278868A2 Novel mutated form of arginine deiminase |
| 01/29/2003 | EP1278818A2 Low ionic strength ophthalmic compositions |
| 01/29/2003 | EP1278780A2 ESTERIFIED POLYSACCHARIDE PRODUCTS AND $g(G)-LACTONE RING OPENED KETENE DIMER PRODUCTS CONTAINING THE COMPOSITIONS, AND PROCESS OF MAKING THE SAME |
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278772A2 Glucagon antagonists |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278766A2 Polynucleotides for diagnosing mammary gland cancer |
| 01/29/2003 | EP1278758A1 Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs |
| 01/29/2003 | EP1278551A2 Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| 01/29/2003 | EP1278549A2 Cyclodextrin containing glycopeptide antibiotic compositions |
| 01/29/2003 | EP1278548A2 Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278536A1 Depletion method of blood plasma ascorbate |
| 01/29/2003 | EP1278524A1 Medical combinations comprising mometasone and salmeterol |
| 01/29/2003 | EP1278523A2 Combination of progesterone and mifepristone for cancer therapy |
| 01/29/2003 | EP1278515A1 Pharmaceutical formulation comprising carrier beads coated with a layer of valaciclovir |
| 01/29/2003 | EP1278512A2 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 01/29/2003 | EP1278511A1 Use of a lacrophyl preparation in eye-drops containing therapeutically active compounds |
| 01/29/2003 | EP1278495A1 Topical compositions containing prostaglandin e 1? |
| 01/29/2003 | EP1278494A1 Device and method for treating urinary incontinence in females |
| 01/29/2003 | EP1278412A2 Polymer conjugates of ara-c and ara-c derivatives |
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine |
| 01/29/2003 | EP0754192B1 Circularly permuted ligands and circularly permuted chimeric molecules |
| 01/29/2003 | EP0706378B1 New pharmaceutical formulation |
| 01/29/2003 | CN1394141A Fulvestrant formulation |
| 01/29/2003 | CN1394140A Prostaglandin compositions and method of treatment for male erectile dysfunction |
| 01/29/2003 | CN1394136A Instant granules and process for their formulation |
| 01/29/2003 | CN1393484A Inclusion compound of ginsenoside RG3 and hydroxypropyl-beta-cyclodextrin and its preparation and preparing process |
| 01/29/2003 | CN1393268A Process for preparing lipoid as precursor of medicine carrier |
| 01/29/2003 | CN1393267A Medicine releasing system of aliphatic polylactone mixture |
| 01/29/2003 | CN1393218A Biodegradable durable medicine releasing system |
| 01/29/2003 | CN1393217A Release system for hydrophilic medicines containing polyether |
| 01/29/2003 | CN1099894C Vaccine composition for eliciting immune response against N-glycolylated gangliosides and its use |
| 01/29/2003 | CN1099893C Sustained-release preparation |
| 01/29/2003 | CN1099868C Vesicles with controlled release of actives |
| 01/28/2003 | US6512118 Camptothecin derivatives |
| 01/28/2003 | US6512101 Branched hydrazone linkers |
| 01/28/2003 | US6512096 Prostate cell surface antigen-specific antibodies |
| 01/28/2003 | US6512072 Formulation for depositing a film on a substrate comprising 5 to79.9 wt. % of an alkylene trialkoxy terminated polysiloxane; 0.01 to 5 wt. % of a catalyst; 20 to 94.99 to wt % of a volatile diluent, and, optionally, 0.01 to 5 wt. % of an |
| 01/28/2003 | US6512023 An adhesive composition includes a polymerizable adhesive monomer, at least one vapor phase stabilizer, and at least one liquid phase stabilizer. The combination of at least one vapor phase stabilizer and at least one liquid phase |
| 01/28/2003 | US6511972 Stable oral pharmaceutical formulations comprising amoxycillin trihydrate and potassium clavulanate |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511681 Solubility and bioavailability of azole antifungal medicaments |
| 01/28/2003 | US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer |
| 01/28/2003 | US6511668 Silicon oxide powder and process for manufacturing thereof, and cosmetic preparation, micelle holding powder, and perfume holding powder, using the same |
| 01/28/2003 | US6511661 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract |
| 01/28/2003 | US6511650 Preparing porous hydrogel products |
| 01/28/2003 | US6511477 Administering encapsulated drugs such as antiarrythmia agents, so that there is preferential transportation due to particle sizes by lymphs; biodegradable time-release agents for prophylaxis of cardiovascular disorders |
| 01/28/2003 | CA2245269C Solid pharmaceutical dispersions with enhanced bioavailability |
| 01/28/2003 | CA2163003C Solubilizer and external preparations containing the same |
| 01/28/2003 | CA2078869C Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use |
| 01/28/2003 | CA2030962C Improvements relating to the administration of pharmaceutical agents |
| 01/23/2003 | WO2003006993A2 Gel compositions |
| 01/23/2003 | WO2003006681A1 Organometallic probe |
| 01/23/2003 | WO2003006608A2 Enhancement of transfection of dna into the liver |
| 01/23/2003 | WO2003006591A1 8-tetradecenal serving as an odorous or aromatic substance |
| 01/23/2003 | WO2003006568A1 Pyrrolidonoethyl (meth)acrylate containing pressure sensitive adhesive compositions |
| 01/23/2003 | WO2003006531A1 Keratin-based products and methods for their productions |
| 01/23/2003 | WO2003006501A2 G-csf conjugates |
| 01/23/2003 | WO2003006491A2 Peptide-based compounds for targeting intergin receptors |
| 01/23/2003 | WO2003006434A1 Metal complexes for use in boron neutron capture therapy |
| 01/23/2003 | WO2003006371A1 N,n-dinitramide salts as solubilizing agents for biologically active agents |
| 01/23/2003 | WO2003006070A2 Improved chelator conjugates |
| 01/23/2003 | WO2003006068A1 Gene therapy for dry eye syndrome |
| 01/23/2003 | WO2003006066A1 Mixed complexes for masking the taste of bitter active substances |
| 01/23/2003 | WO2003006065A2 Pna conjugate for the treatment of diseases associated with hiv |
| 01/23/2003 | WO2003006064A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | WO2003006063A2 Formulation comprising fulvestrant |
| 01/23/2003 | WO2003006053A1 HUMAN INTERFERON-β FORMULATIONS |
| 01/23/2003 | WO2003006052A1 Sustained-release compositions for injection and process for producing the same |
| 01/23/2003 | WO2003006049A1 Gonadotropin releasing hormone antagonists in gel-forming concentrations |
| 01/23/2003 | WO2003006046A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 01/23/2003 | WO2003006034A2 Herbal formulation |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006009A1 Compositions for reducing or preventing cellulite in mammalian skin |
| 01/23/2003 | WO2003005995A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | WO2003005991A1 A core formulation |
| 01/23/2003 | WO2003005989A2 Granulates containing liposoluble substances and a process for the preparation thereof |
| 01/23/2003 | WO2003005988A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 01/23/2003 | WO2003005978A1 Remedy against skin diseases |
| 01/23/2003 | WO2003005961A2 A controlled release biodegradable gel matrix |
| 01/23/2003 | WO2003005959A2 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | WO2003005952A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | WO2003005951A2 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/23/2003 | WO2003005944A1 Sequential drug delivery systems |
| 01/23/2003 | WO2003005941A2 Insert for the treatment of dry eye |
| 01/23/2003 | WO2003005822A1 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 01/23/2003 | WO2002062947A9 Hematopoietic growth factor inducible neurokinin-1 gene |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055530A3 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 01/23/2003 | WO2002049673A3 Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| 01/23/2003 | WO2002049617A3 Self forming, thermodynamically stable liposomes and their applications |
| 01/23/2003 | WO2002049614A3 Intraocular irrigating solution having improved flow characteristics |